eftilagimod alfa + atezolizumab

Eftilagimod alfa + atezolizumab is an investigational combination immunotherapy being developed for the treatment of various cancers and infections. Eftilagimod alfa (efti; IMP321) is a recombinant soluble human LAG-3 Ig fusion protein and a first-in-class MHC class II agonist that activates antigen-presenting cells (APCs) such as dendritic cells, triggering a Th1 response and T-cell proliferation. Atezolizumab is a humanized monoclonal antibody targeting programmed death-ligand 1 (PD-L1), which acts as an immune checkpoint inhibitor. By combining APC activation via the MHC class II pathway with immune checkpoint blockade of the PD-1/PD-L1 pathway, the combination aims to synergistically enhance anti-tumor immune responses. Immutep's patent estate covers the combination of eftilagimod alfa with PD-1 pathway inhibitors, including atezolizumab.